Diagnostic value of urinary nuclear matrix protein 22 combined with bladder tumor antigen detection for bladder cancer / 肿瘤研究与临床

ABSTRACT

Objective:To investigate the diagnostic value of urinary nuclear matrix protein 22 (NMP22) combined with bladder tumor antigen (BTA) detection for bladder cancer, in order to provide a laboratory basis for early screening of bladder cancer.Methods:The clinicopathological data of 315 suspected bladder cancer patients in Baoji Central Hospital in Shaanxi Province from August 2018 to July 2019 were retrospectively analyzed. Among the patients, 248 patients with bladder cancer and 67 patients with urological benign disease were diagnosed by surgical pathology or cystoscope biopsy, and 100 healthy people that took the normal physical examination in the same period were selected as healthy control group. The levels of urinary NMP22 and BTA were detected by enzyme-linked immunosorbent assay (ELISA).Results:The expression levels of urinary NMP22 in the bladder cancer group, urological benign disease group and healthy control group were (28.4±8.8) ng/ml, (12.7±3.0) ng/ml and (4.3±1.5) ng/ml, and the difference was statistically significant ( F = 26.41, P < 0.05); BTA expression levels were (25.1±8.1) ng/ml, (10.4±2.9) ng/ml and (6.4±2.4) ng/ml, and the difference was statistically significant ( F = 23.62, P < 0.05). The differences in the expression levels of urinary NMP22 and BTA in bladder cancer patients with different TNM stages and pathological grades were statistically significant (all P < 0.05). The area under the receiver operating characteristic curve, sensitivity, and negative predictive value of the combined detection of urinary NMP22 and BTA were 0.895, 96.98%, and 61.11%, respectively, which were higher than the single detection, and the differences were statistically significant (all P < 0.05). The cut-off values of urinary NMP22 and BTA for diagnosis of bladder cancer were 32.42 ng/ml and 29.13 ng/ml, respectively. Conclusions:The combined detection of urinary NMP22 and BTA has a high clinical value for the diagnosis of bladder cancer. The detection has the advantages of simple, rapid, non-invasive, and mass screening, which is worthy of clinical promotion.